Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Change in Accured Expenses (2013 - 2026)

Scynexis' (SCYX) quarterly Change in Accured Expenses came in at $655000.0 in Q2 2026, up 528.1% on a YoY basis from $104282.0 in Q2 2025, and up 146.39% quarter-over-quarter from -$1.4 million in Q1 2026.

Analysis

Scynexis (SCYX) Change in Accured Expenses (2013 - 2026) Analysis & Trends

Scynexis (SCYX) has reported Change in Accured Expenses for 14 consecutive years, with $655000.0 the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Change in Accured Expenses rose 528.1% year-over-year to $655000.0; the trailing twelve-month figure through Jun 2026 stood at -$443000.0 (up 85.33% YoY), and the FY2025 full-year result was -$1.0 million, up 72.93% from the prior year.
  • Change in Accured Expenses climbed to $655000.0 in Q2 2026 per SCYX's latest filing, from -$1.4 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $3.7 million in Q2 2022 and bottomed at -$5.8 million in Q1 2023.
  • Historically, Change in Accured Expenses has averaged -$508777.8 across 5 years, with a median of -$71000.0 in 2022.
  • The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses plunged 2125.97% in 2024, then jumped 2870.0% in 2025.
  • Over 5 years, Change in Accured Expenses stood at -$70000.0 in 2022, then retreated by 10.0% to -$77000.0 in 2023, then slumped by 2125.97% to -$1.7 million in 2024, then soared by 100.99% to $17000.0 in 2025, then surged by 3752.94% to $655000.0 in 2026.
  • According to Business Quant data, Change in Accured Expenses over the past three periods registered $655000.0, -$1.4 million, and $17000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 852.00 Mn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 338.00 Mn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 222.50 Mn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 492.70 Mn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 11.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 61.62 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn -49.70 Mn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -13.91 Mn
10 Scynexis 58.41 Mn -56.29 Mn - 655,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 655,000.00
Mar 31, 2026 -1.41 Mn
Dec 31, 2025 17,000.00
Sep 30, 2025 297,000.00
Jun 30, 2025 -153,000.00
Mar 31, 2025 -1.16 Mn
Dec 31, 2024 -1.71 Mn
Sep 30, 2024 10,000.00
Jun 30, 2024 896,000.00
Mar 31, 2024 -2.89 Mn
Dec 31, 2023 -77,000.00
Sep 30, 2023 -72,000.00
Jun 30, 2023 -68,000.00
Mar 31, 2023 -5.84 Mn
Dec 31, 2022 -70,000.00
Sep 30, 2022 -1.70 Mn
Jun 30, 2022 3.74 Mn
Mar 31, 2022 383,000.00
Dec 31, 2021 -49,000.00
Sep 30, 2021 3.78 Mn